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Abstract. Background and aim of the study: Scant information on the cellular distribution of the five somatostatin receptor
(SSTR) subtypes in the normal prostate and in neoplasms of the prostate has been reported in very few studies in which tech-
niques, such as in situ hybridization histochemistry, autoradiography, and more recently immunohistochemistry, have been ap-
plied. The aim of the study was to examine immunohistochemically the distribution and localization of these 5 subtypes in the
various tissue components in normal prostate.
Materials: The study was conducted in 14 surgical specimens of normal prostate tissue from adenomectomy specimens from
patients with bladder outlet obstruction. The distribution and localization of the 5 somatostatin receptor (SSTR) subtypes was
investigated with an immunohistochemical technique. Specificity of the antibodies against the 5 receptor subtypes was prelimi-
narily investigated.
Results: Close to 90% of secretory cells showed a weak positivity in the cytoplasm, the proportion ranging from 86.3%
(SSTR4) to 89.9% (SSTR5). Strong immunoreactivity was seen in a small proportion of cells, ranging from 0.8% (SSTR3) to
3.2% (SSTR1). For the subtypes 1 and 3 the greatest proportion of basal cells showed a moderate intensity (42.5 and 41.4%,
respectively), strong immunoreactivity being observed only in 18.1 and 15.8% of cells, respectively. For the subtypes 2, 4 and 5,
the majority of cells showed a weak intensity (72.3, 65.7 and 65.1%, respectively). Subtype 1 showed a strong immunoreactivity
in the cytoplasm in 60% of the smooth muscle cells. With subtypes 2, 3 and 4 the greatest proportion of cells showed a weak
intensity (63.4, 89.8 and 81.7%, respectively). With the subtype 5 the majority of cells (59.8%) were negative. Subtype 1 showed
a strong immunoreactivity in the cytoplasm in 98.6% of the endothelial cells. With subtypes 3 and 4 the greatest proportion of
cells showed a weak intensity (73.5 and 56.4%, respectively). With the subtype 2 and 5 the majority of cells were negative (59.1
and 50.7%, respectively).
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Conclusions: Our immunohistochemical study on the SSTRs expands our knowledge in the distribution of these subtypes in the
various tissue components in the prostate. Such an information may prove useful in developing further non-surgical strategies
for the prevention and treatment of benign prostatic hyperplasia and, in particular, of preneoplastic and neoplastic lesions of the
prostate.
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1. Introduction
Somatostatin (SST) is a 14- or 28-amino acid pep-
tide that was originally discovered in 1973 as a hy-
pothalamic neuroendocrine hormone [1]. This peptide
was first considered to inhibit the secretion of growth
hormone from the anterior pituitary gland, but the pres-
ence of this peptide hormone was subsequently de-
tected throughout the body, where it inhibits a number
of physiological processes through suppression of var-
ious peptide hormones, such as pancreatic secretion,
neurotransmission in the central nervous system, and
gut motility [2].
The actions of somatostatin are mediated by specific
somatostatin receptors (SSTR), i.e., SSTR1, SSTR2,
SSTR3, SSTR4 and SSTR5. These receptors belong to
a family of transmembrane domain G-protein-coupled
receptors encoded on five different chromosomes.
These receptor subtypes all share common signal path-
ways such as the inhibition of adenylylcyclase [3], ac-
tivation of phosphotyrosine phosphatase and others,
but some subtypes are also associated with modulation
of inward rectifying K+ channels (SSTR2, 3, 4, 5),
to voltage-dependent Ca2+ channels (SSTR1, 2), and
a Na+/H+ exchanger (SSTR1) [3]. The presence of
these SSTR subtypes has been demonstrated through-
out the body, including the central nervous system [4,
5], gastrointestinal tract [6,7], pancreas [8–10], kidney
[11], prostate [12,13] and others [14–17].
Cloning of five SSTR subtypes has led to the devel-
opment of subtype-selective agonists. Among those,
SSTR2-specific SST analogs octreotide (OCT) and
lantreotide have attracted significant attention in the
past several years. They have been used as new diag-
nostic and treatment modalities for various endocrine
disorders and as adjunctive treatment for a variety of
benign and malignant tumors [18–25]. The antipro-
liferative and antiangiogenic properties of OCT have
been exploited in several clinical trials [26,27].
It is very important to determine which subtypes of
the SSTRs exert their effects on which cells of the
human body. It is nearly impossible to obtain precise
data on the distribution and location of SSTR subtypes
when employing molecular methods, such as North-
ern blot, reverse-transcriptase polymerase chain reac-
tion (RT-PCR), and real-time PCR which treat the tis-
sue as a mass [12,28–33].
To date scant information on the cellular distribution
of these receptor subtypes in the normal prostate and in
neoplasms of the prostate has been reported in very few
studies in which techniques, such as in situ hybridiza-
tion histochemistry, autoradiography, and more re-
cently immunohistochemistry, have been applied [12,
13,29,30,34].
The aim of this study was to examine immunohisto-
chemically the distribution and localization of the five
SSTR subtypes in prostate tissue from adenomectomy
specimens from patients with bladder outlet obstruc-
tion.
2. Materials and methods
2.1. Research protocol
Patients candidate for open surgery adenomectomy
for bladder outlet obstruction due to benign prostatic
hyperplasia were eligible for the study. The criteria for
inclusion were: stage III benign prostatic hyperplasia
requiring surgery, total PSA less than 10 ng/ml and
free/total PSA ratio > 0.20, digital rectal examination
negative, trans-rectal ultrasound negative for prostate
areas suspicious for cancer. Additional criteria for in-
clusion were: absence of upper urinary tract pathol-
ogy; absence of intractable urinary infection; normal
renal and liver function; absence of tumors other than
cutaneous basal cell carcinoma; hepatitis A, B and C
markers negative; HIV serology negative; and absence
of previous hormonal treatments, including finasteride
and dutasteride. The research protocol was approved
by the Ethics Committee of Institution of the individual
authors. This study was designed as the initial step in a
larger investigation on tissue distribution and localiza-
tion of the 5 somatostatin receptor subtypes in preneo-
plastic and neoplastic lesions of the prostate, with the
aim of developing tissue targets for non-surgical treat-
ment strategies.
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2.2. Human tissues
The study was conducted in the normal tissue from
14 cases of adenomectomy specimens from patients
with bladder outlet obstruction due to benign prosta-
tic hyperplasia. A signed consent was obtained from
each patient. The surgical intervention was made in the
urology service of the urologists authors of this paper.
The specimens were fixed in 10% buffered formalin for
24–48 h. Pathology evaluation of all cases was done
at the Section of Pathological Anatomy of the United
Hospitals and Polytechnic University of the Marche
Region, Ancona, Italy. Even though a complete sam-
pling procedure was not applied, a generous sampling
of each specimen was done. The material was then
embedded in paraffin and tissue section of 5 microns
of thickness were stained with hematoxylin and eosin.
There were no cases with prostate cancer or high grade
prostatic intraepithelial neoplasia. Acute and chronic
inflammation was seen focally in 4 cases.
2.3. Antibody against somatostatin receptor subtypes
For immunohistochemistry, all rabbit polyclonal
anti-SSTR subtype antibodies were commercially ob-
tained from Chemicon® International Inc. (Temecula,
CA, USA). Dilution of the antibodies used is shown
in Table 1. Positive control experiments included nor-
mal human pancreas and/or anterior pituitary gland ob-
tained from surgery and autopsy, respectively. Nega-
tive controls were used for the tested antibodies; the
primary antibody was replaced by rabbit non-immune
serum.
2.4. Immunohistochemistry
Ten percent formalin-fixed, paraffin-embedded tis-
sue blocks were serially cut into 5 µm thick sections
which were mounted on silane-coated slides. The sec-
tions were then dewaxed in xylene and rehydrated
through a graded series of ethanol. Antigen retrieval
was done by microwave treatment for 20 min at 98◦C
using 0.01 M citric acid buffer pH 6.0. Endogenous
peroxidase activity was quenched by incubating the
sections in 3% hydrogen peroxide for 10 min at room
temperature. Non-specific binding sites were blocked
through pre-incubation with 1% albumin bovine in
PBS for 20 min at room temperature. Reacted tissue
sections were then incubated with the antibodies for
each SSTR subtype for 18 h at 4◦C. Antigen-antibody
complex was subsequently visualized using the Envi-
sion™ Detection System kit peroxidase/DAB (DAKO,
Glustrop, Denmark) and counterstained with hema-
toxylin.
2.5. Evaluation of immunohistochemistry
At least 4,000 cells were counted by one of us (DM)
in contiguous 400× microscopic fields in each case,
separately for benign secretory epithelium, basal cells,
smooth muscle cells of the stroma and endothelial
cells. Immunostaining was evaluated for the follow-
ing three cell components: cytoplasm, membrane and
nucleus. Staining intensity was classified as negative,
weak (+), moderate (++) or strong (+++). In each
case the percentage of cells with negative, weak, mod-
erate or strong immunoreactivity was calculated and
reported in this study. For each groups the mean and
standard deviation were then evaluated.
2.6. Chromogranin A immunostaining
To determine the co-localization of SSTR subtypes
and chromogranin A, immunostaining for chromo-
granin A on serial tissue sections was done as previ-
ously described [35].
Table 1
Characteristics of the polyclonal antibodies used in immunohistochemistry
Antibody Type Immunogen∗ Dilution Source
i.e., synthetic peptide from:
SSTR1 Rabbit C-terminal domain of human SSTR1 1/300 Chemicon International Inc., USA
SSTR2 Rabbit 2nd extracellular domain of human SSTR2 1/100 Chemicon International Inc., USA
SSTR3 Rabbit C-terminal domain of human SSTR3 1/300 Chemicon International Inc., USA
SSTR4 Rabbit N-terminal extracellular domain of human SSTR4 1/400 Chemicon International Inc., USA
SSTR5 Rabbit C-terminal domain of human SSTR5 1/200 Chemicon International Inc., USA
“Visualization System” ENVISION™ – Ready-to-use Dako, Denmark
∗From manufacturer’s data sheet.
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2.7. Assessment of antibody specificity
In order to evaluate the specificity of the five rab-
bit polyclonal anti-SSTR antibodies employed in this
study, we performed western blot (WB) experiments
on a prostate tissue extract. Briefly, a prostate tis-
sue sample was homogenized at 10% (wt/vol) in Tris-
buffered saline (TBS; 0.05 M Tris/0.2 M NaCl, pH 7.4)
containing 1% Nonidet P-40 and 1% sodium deoxy-
cholate (DOC). Homogenate was clarified at 500g
for 15 min at 4◦C. Protein concentration in the su-
pernatant was determined by Bio-Rad protein assay.
Six individual 100 µg aliquots of prostate homogenate
were mixed with Laemmli buffer, heated to 100◦C
for 10 min, then run on a 10% SDS/PAGE gel and
transferred onto a nitrocellulose membrane. The mem-
brane was blocked with 5% (wt/vol) nonfat dry milk
in TBS containing 0.1% Tween 20 (TBST) for 1 h at
room temperature, then cut in six vertical parts sep-
arated by color molecular markers. Each individual
membrane was then independently probed overnight
at 4◦C with one of the five anti-SSTR reagents at a
concentration of 2.5 µg/ml in TBS; the sixth mem-
brane was incubated with non immune rabbit IgG
(Santa Cruz Biotechnology, Heidelberg, Germany) at
the same concentration. After five washes in TBST,
membranes were incubated for 45 min at room tem-
perature with horseradish peroxidase-conjugated goat
anti-rabbit IgG (Santa Cruz Biotechnology, Heidel-
berg, Germany) diluted 1:5,000 in TBS. Membranes
were then washed five times in TBST and visualized
with enhanced chemiluminescence reagent (Pierce)
by Chemi-Doc (Bio-Rad Laboratories, Hercules, CA,
USA) analysis system.
3. Results
Table 2 summarizes the clinical features of the
14 patients.
3.1. Secretory cells of the ducts and acini
None of the cases was negative. Immunoreactivity
was primarily detected in the cytoplasm, in the peri-
nuclear region and cell membrane in all SSTR sub-
types. In all the cases and for all the receptor sub-
types, close to 90% of cells showed a weak positivity
in the cytoplasm, the proportion ranging from 86.3%
(SSTR4) to 89.9% (SSTR5). Strong immunoreactivity




Age of the patients 67.0 4.8 61–76
Prostate volume (ml) 102 35.6 55–162
Total serum PSA (ng/ml) 4.8 2.10 1.5–8.4
Serum testosterone (ng/ml)§ 4.3 0.93 3.4–6.0
Serum chromogranin A (ng/ml)∗ 45.9 6.1 35–59
◦ SD, standard deviation, §normal value > 2.7 ng/ml, ∗normal value
19–95 ng/ml.
0.8% (SSTR3) to 3.2% (SSTR1). A distinct positivity
in the cell membrane was seen only with the subtypes
3 and 4. For the former subtype 65.4% of cells showed
a moderate intensity. It was 23.5% for the latter. Nu-
clear staining was seen with subtypes 4 and 5. It was
always weak, and seen in 26% of the former and 58.8%
of the latter. The results are summarized in Table 3.
3.2. Basal cells of the ducts and acini
Immunoreactivity was primarily detected in the cy-
toplasm in all SSTR subtypes. For the subtypes 1 and 3
the greatest proportion of cells showed a moderate
intensity (42.5 and 41.4%, respectively), strong im-
munoreactivity being observed only in 18.1 and 15.8%
of cells, respectively. For the subtypes 2, 4 and 5, the
majority of cells showed a weak intensity (72.3, 65.7
and 65.1%, respectively), whereas a strong immunore-
activity was present in a small proportion of cells, rang-
ing from 0.9% (SSTR2) to 3.2% (SSTR4). The results
are summarized in Table 4.
Figure 1A–D is an example of weak, moderate and
strong immunoreactivity in the basal and secretory
cells. A distinct positivity in the cell membrane is seen
in Fig. 1D.
Figure 1E shows a few scattered cells with strong
immunoreactivity for SSTR1. On serial sections, cells
in the same location are chromogranin A positive.
There was no co-localization between strongly stained
cells for the other four SSTRs and chromogranin A.
3.3. Smooth muscle cells
Subtype 1 showed a strong immunoreactivity in the
cytoplasm in 60% of the cells (Fig. 1F). With sub-
types 2, 3 and 4 the greatest proportion of cells showed
a weak intensity (63.4, 89.8 and 81.7%, respectively).
With the subtype 5 the majority of cells (59.8%) were
negative. There were no cases with a distinct positivity
in the cell membrane. Nuclear staining was seen only
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Table 3
Secretory cells of the ducts and acini (mean and standard deviation of cells for all cases)
Intensity of staining
Negative Positive + Positive ++ Positive +++
SSTR1
C 0 89.8 ± 5.6 7 ± 4.9 3.2 ± 2.3
M 100 0 0 0
N 100 0 0 0
SSTR2
C 0.5 ± 0.3 88.2 ± 2.3 9.7 ± 2.6 1.5 ± 0.6
M 100 0 0 0
N 100 0 0 0
SSTR3
C 0.2 ± 0.3 88.9 ± 2.3 9.9 ± 2.3 0.8 ± 0.6
M 14.3 ± 10 21.3 ± 15 65.4 ± 17 0
N 100 0 0 0
SSTR4
C 0.4 ± 0.8 86.3 ± 4.5 12.3 ± 4.6 1 ± 0.5
M 55 ± 6.4 21.7 ± 7 23.5 ± 8.6 0
N 74.1 ± 18.2 26 ± 19 0 0
SSTR5
C 0 89.9 ± 4 9.1 ± 4 0.9 ± 0.7
M 100 0 0 0
N 41.9 ± 16.6 58.8 ± 17 0 0
C: cytoplasm, M: cell membrane, N: nucleus.
Table 4
Basal cells of the ducts and acini (mean and standard deviation of cells for all cases)
Intensity of staining in the cytoplasm SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
Negative 4.7 ± 5 15.7 ± 8 3.1 ± 3.1 5.7 ± 2.7 9.5 ± 7.5
Positive + 35 ± 30.2 72.3 ± 21 39.4 ± 34 65.7 ± 23.4 65.1 ± 21.8
Positive ++ 42.5 ± 27.5 11 ± 21 41.4 ± 30.2 25.4 ± 25.7 23.9 ± 23
Positive +++ 18.1 ± 15.8 0.9 ± 2.2 15.8 ± 9 3.2 ± 2.7 1.4 ± 2.1
with subtypes 4 and 5, it was always weak and it was
observed in a minority of cells (27.1 and 45.2%, re-
spectively). The results are summarized in Table 5.
3.4. Endothelial cells
Subtype 1 showed a strong immunoreactivity in the
cytoplasm in 98.6% of the cells (Fig. 1F). With sub-
types 3 and 4 the greatest proportion of cells showed
a weak intensity (73.5 and 56.4%, respectively). With
the subtype 2 and 5 the majority of cells were negative
(59.1 and 50.7%, respectively). There were no cases
with a distinct positivity in the cell membrane. Nuclear
staining was not seen. The results are summarized in
Table 6.
3.5. Assessment of antibody specificity
WB analysis of prostate tissue performed with the
panel of five polyclonal anti-SSTR antibodies yielded
single bands as previously described by Helboe et
al. [36].
4. Discussion
Most of the previous studies were based on molec-
ular methods, such as Northern blot, reverse-transcrip-
tase polymerase chain reaction, and real-time PCR,
which treat the tissue as a mass [12,28–33]. This means
that the type of information produced does not allow
the derive data on SSTR cellular location.
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Fig. 1. (A) Weak immunoreactivity for SSTR2 in the basal cells; (B) moderate immunoreactivity for SSTR3 in the basal cells; (C) moderate
immunoreactivity for SSTR5 in the secretory cells; (D) strong immunoreactivity for SSTR4 in the secretory and basal cells. A distinct positivity
in the cell membrane is seen; (E) a few scattered neuroendocrine cells with strong immunoreactivity for SSTR1 (on serial sections cells in the
same location are chromogranin A positive); (F) strong immunoreactivity for SSTR1 in the stromal and endothelial cells.
Molecular techniques such as in situ hybridization
histochemistry and autoradiography have been used in
a limited number of studies [12,13,29,30,37]. The for-
mer basically investigates SSTR mRNA expression in
cryostat sections. The latter also utilizes cryostat sec-
tions and is based on radioligands, i.e., 125I-labeled
somatostatin ligands, such as octreotide. The studies
often dealt with only some of the subtypes, therefore
R. Montironi et al. / Somatostatin receptors in normal prostate tissue 479
Table 5
Smooth muscle cells (mean and standard deviation of cells for all cases)
Intensity of staining in the cytoplasm SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
Negative 0 0 5.6 ± 7.6 8.7 ± 9 59.8 ± 39
Positive + 6.3 ± 8.2 63.4 ± 39 89.8 ± 10 81.7 ± 9 38.9 ± 37
Positive ++ 33 ± 34 35.7 ± 38 4.6 ± 8.6 10 ± 12 1.3 ± 3
Positive +++ 60 ± 40 0.9 ± 2.7 0 0 0
Table 6
Endothelial cells (mean and standard deviation of cells for all cases)
Intensity of staining in the cytoplasm SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
Negative 0 59.1 ± 42 16.1 ± 29 35.7 ± 39 50.7 ± 44
Positive + 0 23.6 ± 30 73.5 ± 34 56.4 ± 40 47.1 ± 42
Positive ++ 1.4 ± 3.6 17.3 ± 35 4.6 ± 8.1 7.8 ± 26 2.1 ± 4.6
Positive +++ 98.6 ± 3.6 0 5.7 ± 21 0 0
Table 7
Studies on the expression and localization of the SSTRs in human prostate tissue∗
Authors Year Technique Receptors Localization Type of tissue
J.C. Reubi et al. 1995 Autoradiography, SSTR1 Smooth muscle, Benign prostatic
in situ SSTR2 endothelium hyperplasia and
hybridization SSTR3 prostate cancer
G. Halmos et al. 2000 RT-PCR SSTR1 Epithelial cells Prostate cancer
SSTR2
SSTR5
N. Dizeyi et al. 2002 IHC, RT-PCR, SSTR1 Epithelial cells, Normal, benign
Western blot SSTR2 stromal cells, prostatic hyperplasia,
SSTR3 endothelium prostate cancer
SSTR4
SSTR5
J. Hansson et al. 2002 In situ SSTR2 Epithelial cells, Benign prostatic
hybridization SSTR4 stromal cells hyperplasia, HGPIN,
prostate cancer
M. Valente et al. 2007 IHC SSTR2A Epithelial cells Cancer∗ ∗
SSTR3
SSTR5
R. Montironi et al. 2008 IHC SSTR1 Secretory cells, Benign prostatic
(present study) SSTR2 basal cells, hyperplasia
SSTR3 smooth muscle stromal cells,
SSTR4 endothelial cells
SSTR5
∗See text for abbreviation. ∗ ∗3 cases of adenocarcinomas with neuroendocrine differentiation of the breast and prostate.
information being only partial. For instance, Reubi
et al. investigated SSTRl, SSTR2, and SSTR3 only
in [33] (Table 7). The type of information that these
two techniques can give is not always comparable to
that obtained with immunohistochemical analysis in
formalin-fixed and paraffin-embedded tissue in which
the architecture and the cytology in the background
is well preserved. In addition, the immunohistochem-
ical technique is much easier to apply than in situ hy-
bridization histochemistry and autoradiography.
When considering localization in our immunohis-
tochemical investigation, although SSTRs are mem-
brane-associated receptors, a significant amount of
staining was seen within the cytoplasm, in the peri-
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nuclear region and some nuclear staining in many im-
munoreactive cells. The interpretation, based on mole-
cular studies suggesting nuclear accumulation of SST
analogs mediated by SSTRs [20,37,38], is that, after
binding their ligand, SSTR-ligand complexes undergo
cellular internalization with progressive intracytoplas-
mic and intranuclear translocation. This hypothesis is
not supported by the studies made by Le Romancer et
al. [39]. This group suggested that the nuclear translo-
cation of SST analogs is mediated by p86-Ku and not
by SSTRs.
The present immunohistochemistry-based study
demonstrated at the microscopic level the degree of ex-
pression and localization of the five SSTR subtypes in
the normal prostate tissue obtained from patients with
clinical diagnosis of benign prostatic hyperplasia and
no clinical evidence of prostate cancer. In particular,
the five subtypes were seen in the secretory and basal
cells lining the ducts and acini as well as in the stromal
and endothelial cells.
Dizeyi et al. [29] published a recent study on
immunohistochemical expression and localization of
the five SSTR subtypes in normal and pathological
prostate tissue obtained from radical prostatectomy
specimens. They demonstrated the presence of SSTR1
and SSTR3 in tumoral and non-tumoral epithelial cells
as well as in the stromal compartment, whereas SSTR4
was found to be confined to epithelial cells, and SSTR5
was not detectable. In particular, they showed the pres-
ence of SSTR1 in a subpopulation of cancerous and
neurondocrine cells, whereas SSTR2 was found in the
stroma, peritumoral blood vessels and tumor cells. Re-
ceptor subtype 3 was demonstrated to be present on the
cell membrane of BPH and malignant areas. A strong
immunoreaction of SSTR4 was found in tumor cells,
as compared with a less intense immunoreaction in ad-
jacent BPH areas. SSTR subtype 5 was not detectable.
There are similarities between our investigation and
that by Dizeyi et al. [29]. In particular, in both stud-
ies it was shown that there was no co-localization of
NE cells (detected with an antibody against chromo-
granin A) with SSTRs, except for SSTR1.
There are differences in results between our study
and that Dizeyi et al. [29] probably due to the types of
antibodies used (in Dizeyi’s study the antibodies were
a private source and not commercially available) as
well as to the fixation quality and time of the speci-
mens. Our study also differs in that we collected infor-
mation on the differential expression of the five recep-
tor subtypes in the secretory cells but also in the basal
cells.
The current study showed that the five SSTR sub-
types are also expressed in the smooth muscle cells of
the prostatic stroma. Subtype 1 was the most intensely
expressed receptor and its location was in the cyto-
plasm. Subtypes 2, 3 and 4 were also seen in the cy-
toplasm with their expression always weak. Close to
60% of the cells were negative for subtype 5. Our find-
ings are similar to those obtained by Reubi et al. [33]
in their molecular study of SSTRl, SSTR2 and SSTR3.
A possible role of the SSTRs in the smooth muscle
could be to influence the release of various growth fac-
tors (i.e., nerve growth factor) known to be synthe-
sized in the stroma. As several of these growth factors
act in a paracrine manner on the glandular part of the
prostate to regulate prostate growth [29], somatostatin
could indirectly regulate biological events in the pro-
static gland through a stromal action. Another possible
role would be a regulatory mechanism dependent on
the SSTR action on the prostate mediated by the pitu-
itary.
The current study also showed the presence of the
five SSTRs in the endothelial cells. In particular, sub-
type 1 showed a strong immunoreactivity in the cyto-
plasm in 98.6% of this type of cells. This type of in-
formation confirms that provided previously by Curtis
et al. [40] and Badway et al. [41] who independently
demonstrated SSTR1 and SSTR2 expression in en-
dothelial cells. The presence of the SSTR subtypes in
endothelial cells in prostate tissue was also reported
by Dizeyi et al. [29]. This group mentioned that peri-
tumoral vessels were intensely stained by the SSTR2
antiserum. In their molecular study in prostate cancer,
Reubi et al. [13,42] observed that many peritumoral
vessels, in particular veins, contain a high density of
SSTRs. SSTR-positive veins were also occasionally
identified in samples of prostate tissue distant from the
prostate tumour as well as in the prostate of the pa-
tient with bladder cancer. Precise actions of somatosta-
tin in endothelial cells have not yet been clarified, but
somatostatin may be involved in regulating endothelial
cell homeostasis and anti-inflammatory effects [43].
An interesting study on the immunohistochemical
expression of somatostatin receptor subtypes 2A in
a series of 107 neuroendocrine tumors from differ-
ent organs was published by Dr. Valente and his co-
workers [34] after the completion of our present in-
vestigation. Our study and that by Dr. Valente et al.
are not fully comparable because we investigated ep-
ithelial and non-epithelial components of the transi-
tion zone of the prostate from patients with bladder
outlet obstruction, whereas the other group dealt with
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the epithelial component of neuroendocrine tumours,
mostly not from the prostate. That study included only
3 cases of adenocarcinomas with neuroendocrine dif-
ferentiation of the breast and prostate. However, there
are differences in the epithelial localization between
our study and that study, being cytoplasmic in our and
membranous and cytoplasmic in the other. The dif-
ferences in tissue localization of this receptor subtype
could be related to differences in the type of tissue and
the type of antibody used in the two studies. Dr. Va-
lente et al. made a proposal of a scoring system that
correlated with somatostatin receptor scintigraphy. It
was behind the scope of our small study to propose a
scoring system.
The main limitation of our study is that immunohis-
tochemistry was not associated with a molecular inves-
tigation. This type of study was done to some extent
by others, including Hansson et al. [12] in human BPH
and prostatic cancer, and Klisovic et al. [20] in human
ocular tissue. The former group investigated SSTR2
and SSTR4 only. The latter investigated SSTR1 and
SSTR2 in particular. Both groups found good corre-
lation between immunohistochemical distribution of
SSTRs with their gene expression.
5. Conclusions
The current study showed that the expression and
location of five SSTR subtypes can be determined in
tissue section of normal prostate tissue. Our findings
confirm the type of information obtained previously by
others when molecular techniques were mostly used
and at the same time expands our knowledge in the lo-
cation of these subtypes in the various tissue compo-
nents of the prostate. Such an information may prove
useful in developing further non-surgical strategies for
the prevention and treatment of benign prostatic hyper-
plasia and, in particular, of preneoplastic and neoplas-
tic lesions of the prostate.
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